Literature DB >> 19220831

Increase in tumour-infiltrating lymphocytes with regulatory T cell immunophenotypes and reduced zeta-chain expression in nasopharyngeal carcinoma patients.

W K Yip1, M A Abdullah, S M Yusoff, H F Seow.   

Abstract

The pathological significance of the mechanisms of tumour immune-evasion and/or immunosuppression, such as loss of T cell signalling and increase in regulatory T cells (T(regs)), has not been well established in the nasopharyngeal carcinoma (NPC) microenvironment. To evaluate the T(reg) immunophenotypes in tumour-infiltrating lymphocytes (TILs), we performed a double-enzymatic immunostaining for detection of forkhead box P3 (FoxP3) and other markers including CD4, CD8, and CD25 on 64 NPC and 36 non-malignant nasopharyngeal (NP) paraffin-embedded tissues. Expression of CD3 zeta and CD3 epsilon was also determined. The prevalence of CD4(+)FoxP3(+) cells in CD4(+) T cells and the ratio of FoxP3(+)/CD8(+) were increased significantly in NPC compared with those in NP tissues (P < 0.001 and P = 0.025 respectively). Moreover, the ratio of FoxP3(+)/CD25(+)FoxP3(-) in NPC was significantly lower than that in NP tissues (P = 0.005), suggesting an imbalance favouring activated phenotype of T cells in NPC. A significant negative correlation between the abundance of FoxP3(+) and CD25(+)FoxP3(-) cells (P < 0.001) was also identified. When histological types of NPC were considered, a lower ratio of FoxP3(+)/CD25(+)FoxP3(-) was found in non-keratinizing and undifferentiated carcinomas. Increased CD4(+)FoxP3(+)/CD4(+) proportion and FoxP3(+)/CD8(+) ratio were associated with keratinizing squamous cell carcinoma. A reduced expression of CD3 zeta in TILs was found in 20.6% of the NPC tissues but none of the NP tissues. These data provide evidence for the imbalances of T(reg) and effector T cell phenotypes and down-regulation of signal-transducing molecules in TILs, supporting their role in suppression of immune response and immune evasion of NPC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19220831      PMCID: PMC2669517          DOI: 10.1111/j.1365-2249.2008.03793.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  56 in total

1.  The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.

Authors:  Dominik Wolf; Anna M Wolf; Holger Rumpold; Heidi Fiegl; Alain G Zeimet; Elisabeth Muller-Holzner; Martina Deibl; Guenther Gastl; Eberhard Gunsilius; Christian Marth
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

2.  Analysis of the expression of Fas-L in nasopharyngeal carcinoma tissues.

Authors:  S T Tsai; S Y Fang; Y T Jin; I J Su; B C Yang
Journal:  Oral Oncol       Date:  1999-07       Impact factor: 5.337

3.  Transient regulatory T-cells: a state attained by all activated human T-cells.

Authors:  Vinodh Pillai; Sterling B Ortega; C K Wang; Nitin J Karandikar
Journal:  Clin Immunol       Date:  2006-12-19       Impact factor: 3.969

Review 4.  Expression of CD40 and CD40L on tumor cells: the role of their interaction and new approach to immunotherapy.

Authors:  N M Bereznaya; V F Chekhun
Journal:  Exp Oncol       Date:  2007-03

5.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

6.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

Authors:  Qiang Gao; Shuang-Jian Qiu; Jia Fan; Jian Zhou; Xiao-Ying Wang; Yong-Sheng Xiao; Yang Xu; Yi-Wei Li; Zhao-You Tang
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

7.  Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells.

Authors:  Mindi R Walker; Deborah J Kasprowicz; Vivian H Gersuk; Angele Benard; Megan Van Landeghen; Jane H Buckner; Steven F Ziegler
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

8.  Interleukin-1 alpha gene expression and localization of interleukin-1 alpha protein during tumor promotion.

Authors:  T M Oberyszyn; C L Sabourin; G N Bijur; A S Oberyszyn; L G Boros; F M Robertson
Journal:  Mol Carcinog       Date:  1993       Impact factor: 4.784

9.  Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.

Authors:  Sarah E Allan; Sarah Q Crome; Natasha K Crellin; Laura Passerini; Theodore S Steiner; Rosa Bacchetta; Maria G Roncarolo; Megan K Levings
Journal:  Int Immunol       Date:  2007-02-27       Impact factor: 4.823

10.  High serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: pathogenic and clinical relevance.

Authors:  Laura Caggiari; Massimo Guidoboni; Emanuela Vaccher; Luigi Barzan; Giovanni Franchin; Annunziata Gloghini; Debora Martorelli; Paola Zancai; Maria Teresa Bortolin; Mario Mazzucato; Diego Serraino; Antonino Carbone; Paolo De Paoli; Riccardo Dolcetti
Journal:  Infect Agent Cancer       Date:  2007-03-01       Impact factor: 2.965

View more
  9 in total

1.  Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.

Authors:  Sharon D Stoker; Zlata Novalić; Maarten A Wildeman; Alwin D R Huitema; Sandra A W M Verkuijlen; Hedy Juwana; Astrid E Greijer; I Bing Tan; Jaap M Middeldorp; Jan Paul de Boer
Journal:  J Cancer Res Clin Oncol       Date:  2015-04-29       Impact factor: 4.553

2.  A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma.

Authors:  W K Chia; W-W Wang; M Teo; W M Tai; W T Lim; E H Tan; S S Leong; L Sun; J J Chen; S Gottschalk; H C Toh
Journal:  Ann Oncol       Date:  2011-08-04       Impact factor: 32.976

3.  Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas.

Authors:  Chih-Ching Wu; Chia-Wei Hsu; Chi-De Chen; Chia-Jung Yu; Kai-Ping Chang; Dar-In Tai; Hao-Ping Liu; Wen-Hui Su; Yu-Sun Chang; Jau-Song Yu
Journal:  Mol Cell Proteomics       Date:  2010-02-01       Impact factor: 5.911

4.  The immunologic advantage of recurrent nasopharyngeal carcinoma from the viewpoint of Galectin-9/Tim-3-related changes in the tumour microenvironment.

Authors:  Tseng-Cheng Chen; Chao-Hsien Chen; Cheng-Ping Wang; Pei-Hsuan Lin; Tsung-Lin Yang; Pei-Jen Lou; Jenq-Yuh Ko; Chen-Tu Wu; Yih-Leong Chang
Journal:  Sci Rep       Date:  2017-09-04       Impact factor: 4.379

5.  Mechanisms of Epstein-Barr virus nuclear antigen 1 favor Tregs accumulation in nasopharyngeal carcinoma.

Authors:  Jie Wang; Yunfan Luo; Pei Bi; Juan Lu; Fan Wang; Xiong Liu; Bao Zhang; Xiangping Li
Journal:  Cancer Med       Date:  2020-06-22       Impact factor: 4.452

6.  EBV+ tumors exploit tumor cell-intrinsic and -extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22.

Authors:  Aparna Jorapur; Lisa A Marshall; Scott Jacobson; Mengshu Xu; Sachie Marubayashi; Mikhail Zibinsky; Dennis X Hu; Omar Robles; Jeffrey J Jackson; Valentin Baloche; Pierre Busson; David Wustrow; Dirk G Brockstedt; Oezcan Talay; Paul D Kassner; Gene Cutler
Journal:  PLoS Pathog       Date:  2022-01-13       Impact factor: 6.823

Review 7.  Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options.

Authors:  Rina Jiromaru; Takashi Nakagawa; Ryuji Yasumatsu
Journal:  Cancer Manag Res       Date:  2022-09-12       Impact factor: 3.602

8.  Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways.

Authors:  Yi-Lan Zhang; Jiang Li; Hao-Yuan Mo; Fang Qiu; Li-Min Zheng; Chao-Nan Qian; Yi-Xin Zeng
Journal:  Mol Cancer       Date:  2010-01-10       Impact factor: 27.401

9.  The value of hemoglobin-to-red blood cell distribution width ratio (Hb/RDW), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) for the diagnosis of nasopharyngeal cancer.

Authors:  Zhongyuan Lin; Xuan Zhang; Yu Luo; Yanyun Chen; Yulin Yuan
Journal:  Medicine (Baltimore)       Date:  2021-07-16       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.